Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595128 | 1.00 | KMT2A (0.60) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL2258501 | 0.91 | KMT2A (0.70) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL8816529 | 0.89 | CASP3 (0.56) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL3238951 | 0.84 | CASP3 (0.62) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL10488508 | 0.83 | CASP3 (0.59) | KMT2ACASP3SMN1; SMN2CYP1B1MAPT | |
| SCHEMBL17029125 | 0.83 | CASP3 (0.66) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL8358791 | 0.83 | CASP3 (0.62) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL1200935 | 0.83 | KMT2A (0.65) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL29425579 | 0.83 | KMT2A (0.60) | KMT2ACASP3NPSR1PKMTSHR | |
| SCHEMBL7101624 | 0.83 | KMT2A (0.60) | KMT2ACASP3NPSR1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3668881-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11464775-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-6153641-A | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2000-11-28 | — | — | US | disclosed |
| EP-1042317-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000002877-A2 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
| WO-1999032483-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | disclosed |
| EP-0925296-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998011102-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1998-03-19 | — | — | WO | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4598077-A | Amidine derivatives and cardiotonic compositions | TORII & CO. LTD. (JP) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | KMT2A 701/4885CASP3 3845/4885NPSR1 3584/4885 |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | KMT2A 578/4885CASP3 3784/4885NPSR1 3219/4885 |
| US-11464775-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | KMT2A 701/4885CASP3 3845/4885NPSR1 3584/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | KMT2A 578/4885CASP3 3784/4885NPSR1 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.